A new trading day began on Friday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price up 11.90% from the previous day of trading, before settling in for the closing price of $2.1. CTMX’s price has ranged from $0.40 to $3.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -96.94%. With a float of $136.67 million, this company’s outstanding shares have now reached $164.91 million.
Let’s determine the extent of company efficiency that accounts for 121 employees. In terms of profitability, gross margin is 100.0%, operating margin of 24.37%, and the pretax margin is 28.35%.
CytomX Therapeutics Inc (CTMX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 17.12%, while institutional ownership is 34.32%. The most recent insider transaction that took place on Jun 16 ’25, was worth 28,540. In this transaction Chief Financial Officer of this company sold 10,614 shares at a rate of $2.69, taking the stock ownership to the 226,271 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Chief Financial Officer sold 1,641 for $2.95, making the entire transaction worth $4,841. This insider now owns 199,385 shares in total.
CytomX Therapeutics Inc (CTMX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.07 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -96.94% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.57, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Looking closely at CytomX Therapeutics Inc (NASDAQ: CTMX), its last 5-days average volume was 1.76 million, which is a drop from its year-to-date volume of 3.12 million. As of the previous 9 days, the stock’s Stochastic %D was 33.36%.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 72.36%, which indicates a significant decrease from 72.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.15 in the past 14 days, which was lower than the 0.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $1.33. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $2.49. Second resistance stands at $2.63. The third major resistance level sits at $2.86. If the price goes on to break the first support level at $2.12, it is likely to go to the next support level at $1.89. Should the price break the second support level, the third support level stands at $1.75.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 387.55 million, the company has a total of 80,621K Shares Outstanding. Currently, annual sales are 138,100 K while annual income is 31,870 K. The company’s previous quarter sales were 50,920 K while its latest quarter income was 23,530 K.
